Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

(MedPage Today) — The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the market…

Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119806

Author :

Publish date : 2026-02-09 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

Non-Sterile Wipes Tied to Fatal Infection, Officials Say

Nurses Say They Might Return to Hospitals If Employers Made These Changes

Related Posts

These ER Docs Are Being Ousted After 35 Years. They’re Not Going Quietly.

Drug Cuts Albuminuria in Type 1 Diabetic Kidney Disease, Too

Drug breakthrough for children with severe form of epilepsy

Rapid RSV Tests Can Cut Down on Unneeded Antibiotics, Study Suggests

Study Identifies Factors Linked to Early Melanoma Recurrence

Parkinson’s Protein Linked to Faster Alzheimer’s Progression in Women

These ER Docs Are Being Ousted After 35 Years. They’re Not Going Quietly.

Drug Cuts Albuminuria in Type 1 Diabetic Kidney Disease, Too

Drug breakthrough for children with severe form of epilepsy

Rapid RSV Tests Can Cut Down on Unneeded Antibiotics, Study Suggests

Study Identifies Factors Linked to Early Melanoma Recurrence

Parkinson’s Protein Linked to Faster Alzheimer’s Progression in Women

Prolonged Amoxicillin Challenge Checks Penicillin Allergy

Hospital Forms Committee to Review Epstein Ties, Report Says

Categories

Archives